Related Experiment Video
Updated: Jan 14, 2026
06:47
Microfluidics in Assessing Platelet Function
Published on: November 8, 2024
1.5K
The Endothelial-Independent Effect of Desmopressin, In Vitro, on Platelet Function
Michael V Forner1, Etheresia Pretorius2, Chantelle Venter2
1Department of Anesthesiology and Critical Care, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, Western Cape, South Africa, sun.ac.za.
Advances in Hematology
|October 27, 2025
Summary
Desmopressin (DDAVP) enhances platelet activation and microclot formation in vitro, independent of endothelial interactions. This study reveals a direct in vitro effect of DDAVP on platelet function and clotting.
Area of Science:
- Hematology
- Pharmacology
Background:
- Platelets are crucial for primary hemostasis.
- Desmopressin (DDAVP) is known to enhance platelet function via endothelial interaction.
- An alternative, endothelium-independent mechanism for DDAVP's action is hypothesized.
Purpose of the Study:
- To investigate the in vitro effect of Desmopressin (DDAVP) on platelet function.
- To assess DDAVP's impact on microclot formation in plasma proteins.
- To explore potential endothelium-independent mechanisms of DDAVP.
Main Methods:
- Blood samples from 20 healthy volunteers were analyzed.
- DDAVP was added in vitro to test samples.
- Platelet function and microclotting were assessed using PFA-200, viscoelastic (VET), and fluorescence microscopy.
Main Results:
- DDAVP significantly increased TEG MA and decreased K-time in vitro.
- Fluorescence microscopy showed increased platelet activation and microclot formation with DDAVP.
- No significant difference in clotting times was observed with PFA-200 testing.
Conclusions:
- DDAVP demonstrates an in vitro effect on platelet activation and microclot formation.
- This effect appears independent of endothelial interactions, contrasting previous literature.
- This study is the first to show in vitro effects of DDAVP on platelets using VET and microscopy.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
01:22Formation of the Platelet Plug
8.6K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
8.6K